Source: Virtual Congress 2021 – Exacerbations of chronic respiratory diseases, including SARS-CoV-2



Rating:

Share or cite this content

Citations should be made in the following way:
A. Papaioannou (Athens, Greece), E. Fouka (Thessaloniki, Greece), ?. Tzanakis (Crete, Greece), K. ?ntoniou (Crete, Greece), ?. Samitas (Athens , Greece), ?. ?ervas (Athens , Greece), ?. ?ostikas (Ioannina, Greece), ?. Bartziokas (Ioannina, Greece), ?. Porpodis (Thessaloniki, Greece), D. Papakosta (Thessaloniki, Greece), ?. ?zouvelekis (Patras, Greece), I. Gerogianni (Larissa, Greece), ?. ?otsiou (Larissa, Greece), ?. ?akris (Athens, Greece), ?. ?ovina (Athens, Greece), G. Vlachou (Tripoli, Greece), ?. ?arkatos (Heraklion, Greece), S. Vittorakis (Chania, Greece), ?. ?atsoulis (Thessaloniki, Greece), I. Papanikolaou (Corfu, Greece), P. ?atsaounou (Athens, Greece), P. Steiropoulos (Alexandroupolis, Greece), D. Latsios (Drama, Greece), K. Dimakou (Athens, Greece), G. Hillas (Athens, Greece), S. ?ryfon (Thessaloniki, Greece), A. Georgopoulou (Thessaloniki, Greece), P. Avarlis (Kalamata, Greece), P. Bakakos (Athens, Greece), ?. ?arkopooulou (minapaspala@gmail.com, Greece), ?. Gaki (Trikala, Greece), A. Paspala (Thessaloniki , Greece), ?. Kyriakaki (Athens, Greece). SARS-Cov-2 infection in asthma patients treated with biologics. 4057

Member's Comments

No comment yet.

Related content which might interest you: Duration of therapy in hospitalised patients with CAP Source: Annual Congress 2007 - An international perspective of the management of hospitalised patients with community-acquired pneumonia Year: 2007 Evolution of patients with severe asthma treated with mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Comparing pneumonia incidence in COPD patients treated with or without inhaled corticosteroid Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data Year: 2021 Which patients should be treated with anti-IgE? Source: Eur Respir Rev 2007; 16: 85-87 Year: 2007 Add-on omalizumab therapy for patients with severe persistent allergic (IgE-mediated) asthma: identifying which patients to treat and which patients respond Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006 Exacerbations of severe asthma in patients treated with mepolizumab Source: Eur Respir J, 52 (6) 1801127; 10.1183/13993003.01127-2018 Year: 2018 Ceruloplasmine efficacy in patients with asthma exacerbations Source: Annual Congress 2011 - Novel mechanisms in lung injury Year: 2011 ‘Real-life‘ persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study Source: Annual Congress 2011 - Asthma management and response Year: 2011 Characterisation of severe, steroid-dependent asthma patients who initiate biologics versus those who do not Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021 Cost analysis for patients with severe asthma receiving omalizumab treatment Source: International Congress 2019 – Clinical aspects of airway diseases Year: 2019 Differences between asthmatics and nonasthmatics hospitalised with influenza A infection Source: Eur Respir J 2013; 41: 824-831 Year: 2013 10 Year evaluation of patients with severe uncontrolled allergic asthma treated with Omalizumab. Source: International Congress 2018 – Physiological and biological insights in asthma Year: 2018 Follow-up of patients with moderate-severe allergic asthma treated with omalizumab Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010 The effectiveness of anti-IL5 biologics is comparable in previous-smokers and never-smokers with severe asthma Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Two therapy option in patients with uncontrolled asthma Source: International Congress 2018 – Physiological and biological insights in asthma Year: 2018 Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy Source: Eur Respir Rev 2007; 16: 73-77 Year: 2007 Endotypes of severe allergic asthma patients who clinically benefit from Anti-IgE therapy Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD Year: 2018 Physicians judge add-on omalizumab therapy as an effective treatment for patients with severe persistent allergic asthma: a pooled analysis Source: Eur Respir J 2005; 26: Suppl. 49, 49s Year: 2005